4-Methylimidazole (4-MeI) is a widely used chemical, also identified as a by-product of heating foods. In cancer bioassays, 4-MeI induced lung tumors in mice, but not in rats. To establish if metabolic differences could explain species difference in carcinogenicity, this study investigated metabolism of 4-MeI in rat and mouse lung and liver microsomes and S-9 fractions, and in vivo in rats and mice. No metabolites were detected in rat or mouse lung and liver microsomes, or lung S-9 fractions. Male and female F-344 rats and B6C3F1 mice were administered 50 and 150 mg/kg [14C] 4-MeI by gavage. Excreta, exhaled CO2 and volatiles were collected for 48 h. Elimination was mainly via urine, with 79-89% of the radioactivity in urine in rats and 41-70% in mice. Most of the radioactivity (71-88%) in urine was unchanged 4-MeI. Additional radioactive peaks (the largest metabolite was 8-18%) were characterized by LC-MS/MS as 4-hydroxymethylimidazole, its glucuronide, and other oxidized products, including methylhydantoin. 4-MeI was largely excreted unchanged in rats and mice with limited oxidative metabolism and conjugation. 4-MeI was not oxidized in subcellular fractions from rat and mouse lung and liver. Overall, the metabolism of 4-MeI appeared similar between rats and mice.
Metabolism of 4-methylimidazole in Fischer 344 rats and B6C3F1 mice
Fennell, T. R., Watson, S. L., Dhungana, S., & Snyder, R. W. (2019). Metabolism of 4-methylimidazole in Fischer 344 rats and B6C3F1 mice. Food and Chemical Toxicology, 123, 181-194. https://doi.org/10.1016/j.fct.2018.10.032
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Epigenetic biomarkers for smoking cessation
A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood